ClinicalTrials.gg
CompletedNCT04327661Updated Dec 11, 2024Results posted

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

A Phase 3 interventional study of Tradipitant and Placebo in Motion Sickness, sponsored by Vanda Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Motion Sickness with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Motion Sickness · United States.

Enrollment
3rd of 27
366 · median 63
Started
2021
with 2 others
Phase 3
10 of 28
none open now
Registered
13th of 28
by date
Lead sponsor
4 of 28
Vanda Pharmaceuticals

Among the 28 studies in Motion Sickness with a site in United States, this one is the 3rd largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2021, is one of 10 in phase 3, and was the 13th registered.

Motion Sickness

50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.

Browse Motion Sickness studies →

Open to participants now

4 of the 28 studies in Motion Sickness with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Motion Sickness studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Motion Sickness with a site in United States, or all of them as a file.
02

Study summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel

03

Conditions studied

  • Motion Sickness

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of motion sickness
  • Age 18-75

Exclusion criteria

Exclusion Criteria:

  • Nausea-inducing disorder other than motion sickness
  • >40
  • History of intolerance and/or to Neurokinin-1 Receptor antagonists
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Tradipitant High Dose

    Drug: Tradipitant

  • Experimental
    Tradipitant Low Dose

    Drug: Tradipitant

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Prevention of Vomiting Measured by Vomiting Assessment (VA)

    Prevention of vomiting measured by Vomiting Assessment (VA) score in tradipitant high dose. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited. The Count of Participants indicates participants who vomited.

    Time frame: 1 day

07

Results

Posted Dec 11, 2024

Participant flow

Participant flow — Overall Study
MilestoneTradipitant High DoseTradipitant Low DosePlacebo
Started121123122
Completed120123122
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryPrevention of Vomiting Measured by Vomiting Assessment (VA)

Prevention of vomiting measured by Vomiting Assessment (VA) score in tradipitant high dose. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited. The Count of Participants indicates participants who vomited.

Time frame:
1 day
Reported as:
Count of participants · Participants
Prevention of Vomiting Measured by Vomiting Assessment (VA)
ParticipantsTradipitant High DoseTradipitant Low DosePlacebo
Prevention of Vomiting Measured by Vomiting Assessment (VA)222454

Adverse events

Collected over Adverse Events were recorded from time of randomization until the end of study visit, up to 7 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tradipitant High Dose0/120 (0%)0/120 (0%)26/120 (21.7%)
Tradipitant Low Dose0/123 (0%)0/123 (0%)20/123 (16.3%)
Placebo0/122 (0%)0/122 (0%)4/122 (3.3%)
Most frequent other events
Most frequent other events
EventTradipitant High DoseTradipitant Low DosePlacebo
HeadacheNervous system disorders10/1207/1233/122
SomnolenceNervous system disorders10/1208/1231/122
FatigueGeneral disorders10/1205/1230/122

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tradipitant High DoseTradipitant Low DosePlaceboTotal
Mean47.7 ± 14.8449.6 ± 14.4048.6 ± 13.4848.6 ± 14.23
Sex: Female, Male
Sex: Female, Male(Participants)Tradipitant High DoseTradipitant Low DosePlaceboTotal
Female878275244
Male344147122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tradipitant High DoseTradipitant Low DosePlaceboTotal
Hispanic or Latino14121440
Not Hispanic or Latino99102105306
Unknown or Not Reported89320
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tradipitant High DoseTradipitant Low DosePlaceboTotal
American Indian or Alaska Native1023
Asian791127
Black or African American105520
Native Hawaiian or Other Pacific Islander0101
White103105102310
Other0325
Region of Enrollment
Region of Enrollment(participants)Tradipitant High DoseTradipitant Low DosePlaceboTotal
United States121123122366
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Tradipitant High DoseTradipitant Low DosePlaceboTotal
Mean26.785 ± 4.632727.299 ± 4.926528.037 ± 5.183527.377 ± 4.9342
08

Study locations

7 sites
  • Pacific Research Network, LLC
    San Diego, California 92103, United States
  • Santa Monica Clinical Trials
    Santa Monica, California 90025, United States
  • Gulfcoast Psychiatric Associates
    Fort Myers, Florida 33912, United States
  • Harmony Clinical Research
    North Miami Beach, Florida 33162, United States
  • Avita Clinical Research
    Tampa, Florida 33613, United States
  • Beacon Clinical Research
    Quincy, Massachusetts 02169, United States
  • Manhattan Medical Research
    New York, New York 10016, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Apr 2023, 16 months.

Results were first posted in Dec 2024, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Mar 31, 2020
StartActual
Nov 15, 2021
Primary completionActual
Apr 1, 2023
CompletionActual
Apr 12, 2023
Results first posted
Dec 11, 2024
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04327661
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Nov 15, 2021
Primary completion
Apr 1, 2023
Completion
Apr 12, 2023
Results posted
Dec 11, 2024
Last update
Dec 11, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion